Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2025-07-22 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
第四届董事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the first meeting of the fourth board of directors of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the election and appointment of board members and senior management positions such as chairman, general manager, financial officer, and others. The document includes voting results and confirms compliance with legal and procedural requirements. There is no financial data, earnings information, or detailed report content. The document is clearly about board and management changes and appointments, fitting the category of Board/Management Information (MANG). The document length is 2485 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2025-07-22 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using idle proprietary funds to purchase wealth management products. It details the authorization, amounts, counterparties, risk controls, and investment terms related to the company's cash management activities. The document includes specific financial figures and dates but does not present comprehensive financial statements or a full financial report. It is a regulatory disclosure about financing activities related to capital management rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about financing activities, not just a brief notice or certification, so it is not RNS or RPA.
2025-07-13 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It includes specifics about authorized cash management, details of entrusted financial products, risk control measures, and lists of ongoing and matured entrusted financial products. The document is an update on capital management activities related to fundraising proceeds, focusing on the use of idle raised funds for financial management products. It does not contain financial statements, earnings data, or audit information. It is not a report publication announcement since it contains substantive details and is longer than 5,000 characters. The content fits best under Capital/Financing Update (CAP) as it relates to updates on company fundraising and capital usage activities.
2025-07-13 Chinese
关于公司取得原料药CEP证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a CEP certificate for a pharmaceutical raw material. It details the certificate, its validity, and the impact on the company. The document is short (823 characters) and serves as an announcement of a regulatory or business development event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or regulatory certifications. It is not an earnings release, annual report, or any detailed financial or governance report. It is a regulatory announcement about a certification relevant to product quality and market expansion. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2025-07-13 Chinese
重大信息内部报告制度
Governance Information Classification · 95% confidence The document is titled '重大信息内部报告制度' which translates to 'Major Information Internal Reporting System'. It details the internal procedures and obligations for reporting significant information within the company, including definitions of major transactions, related party transactions, major litigation, risks, and changes. It also outlines the responsibilities of directors, senior management, and other insiders in reporting such information to the board and the board secretary. The document is a governance-related internal policy document rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, earnings data, voting results, or any announcement of capital changes. It is a detailed governance and internal control policy document, fitting the category of Governance Information (CGR). The document length is 4690 characters, which is substantive and not a brief announcement or certification. Therefore, the best classification is Governance Information (CGR).
2025-07-03 Chinese
防范控股股东、实际控制人及关联方资金占用管理制度
Governance Information Classification · 95% confidence The document is titled as a management system or policy document regarding the prevention of fund occupation by controlling shareholders, actual controllers, and related parties. It is a detailed internal governance document outlining principles, responsibilities, and procedures related to fund management and prevention of misuse by related parties. It is not a financial report, earnings release, or announcement of voting results. It is not a short announcement or certification but a substantive governance policy. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-07-03 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.